Review





Similar Products

plasminogen activator inhibitor 1  (Innovative Research Inc)
93
Innovative Research Inc plasminogen activator inhibitor 1
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Plasminogen Activator Inhibitor 1, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasminogen activator inhibitor 1/product/Innovative Research Inc
Average 93 stars, based on 1 article reviews
plasminogen activator inhibitor 1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
plasminogen activator inhibitor 1  (Randox)
94
Randox plasminogen activator inhibitor 1
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Plasminogen Activator Inhibitor 1, supplied by Randox, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasminogen activator inhibitor 1/product/Randox
Average 94 stars, based on 1 article reviews
plasminogen activator inhibitor 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
dog plasminogen activator inhibitor 1 serpine1 elisa kit  (Cusabio)
93
Cusabio dog plasminogen activator inhibitor 1 serpine1 elisa kit
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Dog Plasminogen Activator Inhibitor 1 Serpine1 Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dog plasminogen activator inhibitor 1 serpine1 elisa kit/product/Cusabio
Average 93 stars, based on 1 article reviews
dog plasminogen activator inhibitor 1 serpine1 elisa kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
active plasminogen activator inhibitor 1 pai 1  (Innovative Research Inc)
94
Innovative Research Inc active plasminogen activator inhibitor 1 pai 1
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Active Plasminogen Activator Inhibitor 1 Pai 1, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/active plasminogen activator inhibitor 1 pai 1/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
active plasminogen activator inhibitor 1 pai 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
murine plasminogen activator inhibitor type 1 pai 1 elisa  (Innovative Research Inc)
94
Innovative Research Inc murine plasminogen activator inhibitor type 1 pai 1 elisa
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Murine Plasminogen Activator Inhibitor Type 1 Pai 1 Elisa, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine plasminogen activator inhibitor type 1 pai 1 elisa/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
murine plasminogen activator inhibitor type 1 pai 1 elisa - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pai 1 inhibitor activity  (Innovative Research Inc)
94
Innovative Research Inc pai 1 inhibitor activity
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Pai 1 Inhibitor Activity, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pai 1 inhibitor activity/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
pai 1 inhibitor activity - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
plasminogen activator inhibitor 1 pai 1  (Cusabio)
93
Cusabio plasminogen activator inhibitor 1 pai 1
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Plasminogen Activator Inhibitor 1 Pai 1, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasminogen activator inhibitor 1 pai 1/product/Cusabio
Average 93 stars, based on 1 article reviews
plasminogen activator inhibitor 1 pai 1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
plasminogen activator inhibitor 1 pai 1 levels  (Innovative Research Inc)
94
Innovative Research Inc plasminogen activator inhibitor 1 pai 1 levels
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Plasminogen Activator Inhibitor 1 Pai 1 Levels, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasminogen activator inhibitor 1 pai 1 levels/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
plasminogen activator inhibitor 1 pai 1 levels - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
plasminogen activator inhibitor-1 (pai1)  (Janssen)
90
Janssen plasminogen activator inhibitor-1 (pai1)
Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator <t>inhibitor</t> <t>1</t> (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.
Plasminogen Activator Inhibitor 1 (Pai1), supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasminogen activator inhibitor-1 (pai1)/product/Janssen
Average 90 stars, based on 1 article reviews
plasminogen activator inhibitor-1 (pai1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator inhibitor 1 (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia

doi: 10.1016/j.rpth.2025.103319

Figure Lengend Snippet: Hemostatic biomarkers in mouse models of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Levels of hemostatic biomarkers in control mice and mice bearing NB4-Luc cells (APL) or HL-60-Luc2 cells (AML) for (A) cell-free DNA (cfDNA), (B) thrombin-antithrombin complexes (TAT), (C) fibrinogen, (D) plasmin-antiplasmin complexes (PAP), (E) D-dimer, and (F) plasminogen activator inhibitor 1 (PAI-1). Control ( n = 7-9), APL mice ( n = 6 at 28 [ n = 2] or 31 [ n = 4] days for cfDNA, TAT and D-dimer, n = 7 at 29 [ n = 1] or 31 [ n = 6] days for fibrinogen, PAP, and PAI-1), and AML mice ( n = 9 at 45 [ n = 2], 48 [ n = 2], or 50 [ n = 5] days for cfDNA, TAT, and D-dimer. n = 6 at 51 days for fibrinogen, PAP, and PAI-1) are shown. (B, C, E, and F) An ordinary one-way anova followed by Tukey’s test was used for TAT, fibrinogen, D-dimer, and PAI-1; (A and D) the Kruskal–Wallis test followed by Dunn’s test was used for cfDNA and PAP. ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .0001.

Article Snippet: Levels of different biomarkers in plasma were measured using commercial enzyme-linked immunosorbent assays: TAT (Siemens, cat number OWMG15), fibrinogen (Immunology Consultation Laboratory Inc, cat number E-90FIB), PAP (MyBioSource, cat number MBS2512896), D-dimer (Diagnostica Stago, cat number 00947), and plasminogen activator inhibitor 1 (PAI-1; Molecular Innovations, cat number IMSPAI1KTA). cfDNA was measured using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, cat number P11496).

Techniques: Control